The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years, male or female
Histologically or cytologically confirmed primary diagnosis of pancreatic ductal adenocarcinoma (PDAC)
No evidence of distant metastasis (M0)
Underwent R0 radical resection within 3 months prior to enrollment
ECOG performance status of 0-1
Life expectancy ≥3 months
Patient or legal guardian is able to understand the study requirements and willing to provide written informed consent
You may not be if
Prior history of radiotherapy, chemotherapy or surgical treatment for pancreatic cancer
Concurrent severe organ dysfunction or hematologic disorders
Tumor involvement of celiac axis or superior mesenteric artery, locally advanced disease, or presence of distant metastases
Poor general condition deemed unable to tolerate chemotherapy
History of other malignancies within past 5 years (except adequately treated carcinoma in situ of cervix or basal cell carcinoma of skin)
Any severe or uncontrolled systemic disease that may affect risk/benefit assessment, including but not limited to: uncontrolled hypertension, active hepatitis B or C infection, HIV infection
Patient or guardian unable to comprehend study objectives and requirements
Any other condition that in the investigator's judgment would make the patient unsuitable for study participation
Clareo Health | CtDNA-guided Maintenance Therapy in Pancreatic Cancer
